Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin Type A for Overactive Bladder
NCT00168454Phase 2Completed
- Sponsor
- Allergan
- Start
- Jul 2005
- Primary completion
- Jan 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of onabotulinumtoxinA in overactive bladder (OAB) (6 arms), sponsored by Allergan. Primary endpoint: Change in Number of Urinary Urge Incontinence Episodes at Week 12. Started Jul 2005; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00168454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00168454.